SOFIA, Bulgaria and BUDAPEST, Hungary, May 9, 2017 /PRNewswire/ -- Huvepharma EOOD, a global pharmaceutical company with a focus on developing, manufacturing, and marketing human and animal health products, and Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced they have entered into a research collaboration agreement. The collaboration represents the first commercial application of Intrexon's proprietary fungal expression platform to produce a new animal feed enzyme developed by Huvepharma.
"After years of development, we are excited to enter into our first collaboration utilizing our exclusive fungal production system with Huvepharma, a global leader in providing beneficial enzymes to support the food and agricultural industries. Our strain engineering expertise combined with Huvepharma's extensive fermentation capabilities and downstream processing represents a strong combination to efficiently manufacture high-value animal feed products," stated Peter Seufer-Wasserthal, Ph.D., Intrexon's Vice President of Business Development for Europe and Asia.
Karel Bierman, Global Director Enzymes of Huvepharma, added, "We are pleased to collaborate with Intrexon and anticipate this project will not only serve to investigate feasibility of fungal expression for the target enzyme but also open the door to the potential of this platform for production of other feed enzymes based on this very cost effective system."
Utilizing economical fermentation processes, fungal systems are an ideal production platform for enzymes and other feed additives given their high protein yield and substantial secretion capacity. Through the collaboration, Intrexon plans to engineer optimized cell lines to produce the target feed enzyme, and Huvepharma will test their applicability in large-scale production of feed additives. Based on the results of the program, the companies intend to pursue fermentative production of the target enzyme as well as look for additional commercial opportunities utilizing this platform.
The global feed additives market is estimated to exceed $20 billion by 2021 as demand for animal protein continues to increase. To meet these requirements, the nutritional value and the digestibility of animal feed needs to be improved which requires an efficient industrial production of enzymes and other protein-based additives. Enzymes used to enhance the nutritional value of feeds were valued at over $1 billion in 2015.
Huvepharma® is a globally operating company, which has expanded throughout the years by intensive internal evolvement and numerous strategic acquisitions with a focus on developing, manufacturing and marketing of human and animal health products. The highly efficient integrated structure and the talented human capital allow our company to offer competitive and beneficial business conditions. Our state-of-the-art production and quality control equipment ensure top quality products and prove our reputation as a highly trusted producer, very flexible in meeting customers' and partners' needs. To explore more and see how "We add performance to your business" please visit www.huvepharma.com.
About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.
Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information regarding Huvepharma, contact:
Global Director Enzymes
Tel: +32 3 292 8304
Global Director Business Development
Tel: + 359 357 888 70
For more information regarding Intrexon Corporation, contact:
Vice President, Investor Relations
Tel: +1 (561) 410-7052
Marie Rossi, Ph.D.
Director, Technical Communications
Tel: +1 (301) 556-9850
SOURCE Intrexon Corporation